Bob Byrne from Northern California has severe hemophilia A. As a result of bad bleeds when he was younger, Byrne now suffers from arthritis and finds getting around difficult. Without anyone who can offer him care on a daily basis, he decided to get a service dog. MORE: 10 benefits of having…

Bioverativ will collaborate with the Boston imaging company Invicro to use ultrasound imaging to improve the diagnosis and management of joint disease in hemophilia patients. “Through this innovative collaboration with Invicro, we hope to create meaningful progress in hemophilia care by helping people with hemophilia, their caregivers, physicians and treatment team monitor…

Shire announced it is working with MicroHealth to develop a free and secure digital monitoring mobile app for hemophilia A and B patients with antibodies, known as inhibitors, that infer with clotting factors they are using to treat their disease. MicroHealth was co-founded by Aaron Craig, who has hemophilia A,…

Pfizer Rare Disease has developed a new video game and wearable wristband to help hemophilia patients learn more about their condition and promote activity tracking in the U.S. The video game, Hemocraft, and the HemMobile Striiv Wearable wristband were launched at the National Hemophilia Foundation’s 69th Annual Meeting in Chicago, Aug. 24-26.

Life with hemophilia can be challenging but there are ways that you can manage the disease to ensure your child leads as normal a life as possible. To help you navigate your child’s illness and help prevent bleeds, we’ve put together a list of tips. MORE: How to prepare for your child’s…

The U.S. Food and Drug Administration has approved new vial strengths for Octopharma’s hemophilia A therapy Nuwiq, which means patients will need fewer vials per treatment session. Octapharma USA said single-dose strengths of 2,500, 3,000 and 4,000 International Units will be available in the United States in September. The vials are already…

The first patient in a Phase 1/2 clinical trial (“the Alta trial”) designed to assess safety and tolerability of SB-525 gene therapy has received treatment. Sangamo Therapeutics, in a collaboration with Pfizer, is developing  the SB-525 gene therapy to correct the Factor VIII (FVIII) defect in hemophilia A…

The U.S. Food and Drug Administration (FDA) has granted priority review to the therapy emicizumab for patients with hemophilia A with factor VIII inhibitors, Genetech, the drug’s developer, announced. The FDA also announced the acceptance of Genetech’s Biologics License Application (BLA) for emicizumab prophylaxis (preventive) therapy in adults, adolescents and children…

Last updated Dec. 10, 2024, by Susie Strachan Hemophilia has affected people from all walks of life, including royalty, athletes, actors, and advocates. It’s a rare genetic bleeding disorder that mostly affects males, while females are more likely to be carriers. Learn about some of the notable names…